Production (Stage)
NervGen Pharma Corp.
NGENF
$2.42
$0.19558.81%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.63% | -6.89% | -1.34% | 5.96% | 46.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.90% | 38.07% | 15.90% | -10.18% | -22.31% |
| Operating Income | -39.90% | -38.07% | -15.90% | 10.18% | 22.31% |
| Income Before Tax | -24.51% | -5.30% | -20.58% | -20.68% | 4.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.51% | -5.30% | -20.58% | -20.68% | 4.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.51% | -5.30% | -20.58% | -20.68% | 4.31% |
| EBIT | -39.90% | -38.07% | -15.90% | 10.18% | 22.31% |
| EBITDA | -40.56% | -38.56% | -16.31% | 10.08% | 22.38% |
| EPS Basic | -5.74% | 9.24% | -9.78% | -13.11% | 12.39% |
| Normalized Basic EPS | -5.72% | 9.23% | -9.90% | -13.17% | 12.39% |
| EPS Diluted | -5.74% | 9.24% | -9.78% | -13.11% | 12.39% |
| Normalized Diluted EPS | -5.72% | 9.23% | -9.90% | -13.17% | 12.39% |
| Average Basic Shares Outstanding | 17.73% | 13.94% | 9.91% | 5.97% | 6.81% |
| Average Diluted Shares Outstanding | 17.73% | 13.94% | 9.91% | 5.97% | 6.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |